How do you know if you have insulin resistance?

The most accessible clinical indicators are fasting insulin above 10 uIU/mL, waist circumference above 40 inches in men, fasting triglycerides above 150 mg/dL, and HDL below 40 mg/dL. A fasting glucose or HbA1c in the normal range does not exclude insulin resistance, which is why fasting insulin, not glucose alone, is the most sensitive early marker.

Can insulin resistance be reversed?

Yes. Insulin resistance is primarily driven by visceral adiposity, physical inactivity, and dietary refined carbohydrate excess. Aerobic exercise, reduction of refined carbohydrate intake, and visceral fat reduction through the combination of these two consistently improve insulin sensitivity. Fasting insulin falls measurably within weeks of sustained lifestyle change.

Why does the standard lipid panel miss insulin resistance?

The standard lipid panel measures LDL-C, HDL-C, total cholesterol, and triglycerides. A man with insulin resistance typically shows elevated triglycerides and low HDL but may have a normal or even low LDL-C. The metabolic signature that matters, small dense LDL particles, elevated ApoB, elevated fasting insulin, and visceral fat redistribution, is invisible to that panel. The triglyceride-to-HDL ratio above 3.5 in mg/dL units is a simple surrogate: when elevated, it strongly suggests insulin resistance even when fasting glucose is entirely normal.

When does insulin resistance become type 2 diabetes?

Insulin resistance becomes type 2 diabetes when pancreatic beta cells can no longer compensate with sufficient insulin production to maintain normal blood glucose. The transition typically takes years, during which time HbA1c climbs through the prediabetic range. By the time type 2 diabetes is diagnosed, approximately 50 percent of beta cell function has already been lost. The cardiovascular damage, however, begins in the insulin-resistant prediabetic state, not at the diabetes threshold. Men in the prediabetic range already have measurably elevated ApoB, elevated hsCRP, and worse endothelial function than men with normal fasting insulin.

The System Gap

What Is Insulin Resistance? The Metabolic Process Behind Most Cardiovascular Disease.

Insulin resistance drives most cardiovascular disease in middle-aged men. A cardiologist explains the metabolic chain it produces and how to detect it early.

Job Mogire, MD, FACP, FACC · Medically reviewed June 14, 2026

Insulin resistance is the metabolic process driving most of the cardiovascular disease that kills middle-aged men before their time, and it is present in roughly one in three American adults, the majority of whom have never been told. It produces no symptoms for years or decades, the standard annual physical does not routinely measure it, and the lab values that are measured, fasting glucose and LDL, can appear entirely normal while the underlying pathology advances without interruption.

The Mechanism

To understand what goes wrong in insulin resistance, it is necessary to understand what insulin normally does and where in the signaling cascade the failure occurs.

Insulin is a peptide hormone secreted by pancreatic beta cells in direct proportion to rising blood glucose. When insulin binds to its receptor on the surface of a target cell, including skeletal muscle, hepatocytes, and adipocytes, it initiates a phosphorylation cascade. The insulin receptor autophosphorylates, which activates insulin receptor substrate proteins, principally IRS-1 and IRS-2. Phosphorylated IRS-1 recruits phosphatidylinositol 3-kinase (PI3K), which produces the second messenger PIP3, which in turn activates Akt. Downstream of Akt, the primary metabolic effects occur: GLUT4 glucose transporters translocate to the cell surface in muscle and fat, hepatic glycogen synthesis increases, and hepatic glucose production is suppressed. 5 / Solid

The molecular lesion in insulin resistance occurs at IRS-1. Specifically, intracellular accumulation of diacylglycerol (DAG), a lipid intermediate, activates protein kinase C isoforms, particularly PKC-theta in skeletal muscle and PKC-epsilon in the liver. These kinases phosphorylate IRS-1 at serine residues, most critically serine-307, rather than the tyrosine residues that insulin receptor kinase uses. Serine phosphorylation of IRS-1 is inhibitory: it prevents the normal downstream PI3K-Akt signaling from proceeding. The receptor binds insulin. The receptor activates. But the signal does not propagate. 5 / Solid

Where does the intracellular DAG come from? The primary source in the context of visceral obesity is ectopic lipid accumulation. Visceral adipose tissue, unlike subcutaneous fat, drains directly into the portal circulation via the portal vein. When visceral fat mass is elevated, there is chronic delivery of free fatty acids and glycerol into the hepatic portal blood at concentrations far exceeding what the liver can oxidize or package. The excess is re-esterified into triglycerides, and the intermediate in that re-esterification pathway is DAG. The same process occurs in skeletal muscle, where intramyocellular lipid accumulation from elevated circulating free fatty acids produces DAG and activates PKC-theta, blocking IRS-1 signaling in muscle independently of what is happening in the liver. 5 / Solid

The pancreas detects the impaired tissue response to insulin through the resulting blood glucose elevation and compensates by producing more insulin. This is the defining feature of the early phase of insulin resistance: glucose remains normal, or even low-normal, because the beta cells are working harder to maintain it. The price of that compensation is chronic hyperinsulinemia, and it is the elevated insulin level, not the glucose, that initiates most of the downstream cardiovascular damage.

What the Evidence Shows

The relationship between hyperinsulinemia, insulin resistance, and cardiovascular disease has been formally studied since Gerald Reaven’s landmark 1988 Banting Lecture, in which he described what he called Syndrome X: the cluster of insulin resistance, hyperinsulinemia, hypertriglyceridemia, low HDL, and hypertension as a coherent metabolic entity conferring cardiovascular risk independent of LDL. Reaven’s original data, drawn from patients at Stanford, showed that approximately 25% of the nonobese, nondiabetic population had insulin resistance sufficient to produce this phenotype.

The INTERHEART study, a case-control study of 15,152 myocardial infarction cases and 14,820 controls across 52 countries published in The Lancet in 2004, identified the combination of abdominal obesity and dyslipidemia as the most powerful attributable risk factor for acute MI in the study population, accounting for a population-attributable risk of approximately 49% in men. The waist-to-hip ratio, the study’s marker for abdominal adiposity, showed an odds ratio of 1.62 for MI across all regions. The lipid ratio used (ApoB/ApoA-I) reflected the small-dense LDL phenotype characteristic of insulin resistance-driven VLDL overproduction.

The Multi-Ethnic Study of Atherosclerosis (MESA), which followed 6,814 adults free of clinical cardiovascular disease at baseline, published data in 2012 in the Journal of the American College of Cardiology showing that fasting insulin in the highest quartile was independently associated with incident coronary artery disease after adjustment for traditional risk factors, with a hazard ratio of 1.56 (95% CI 1.08 to 2.24) compared to the lowest quartile. Critically, this association was present in individuals without diabetes or metabolic syndrome at baseline, meaning insulin resistance was conferring cardiovascular risk before it produced any of the diagnostic criteria currently used to identify it.

A 2016 analysis from the Nurses’ Health Study and Health Professionals Follow-Up Study, combined to include over 170,000 participants with more than 20 years of follow-up, published in JAMA Internal Medicine, demonstrated that the trajectory of fasting insulin over time was more predictive of cardiovascular events than a single baseline measurement. Men whose fasting insulin rose over a five-year period had a cardiovascular event rate approximately double that of men whose fasting insulin remained stable, even when both groups began with insulin levels in the reference range.

The CARDIA (Coronary Artery Risk Development in Young Adults) study added mechanistic specificity by demonstrating that insulin resistance in young adulthood, measured by the homeostatic model assessment (HOMA-IR), predicted coronary artery calcification 25 years later, with an odds ratio of 2.1 per standard deviation increase in HOMA-IR. This finding, published in Diabetes Care in 2015, confirms that the cardiovascular damage accumulates long before clinical disease appears and decades before standard screening would flag anything.

The cardiovascular mechanism is not simply about glycemic damage. Hyperinsulinemia promotes visceral fat deposition directly by suppressing lipolysis and stimulating lipogenesis in visceral adipocytes. More visceral fat increases free fatty acid delivery to the liver, further stimulating VLDL production. The liver responds to hyperinsulinemia with paradoxical resistance to its glucose-suppressive effects while remaining fully sensitive to its lipogenic effects, a phenomenon described by researchers at the University of California San Francisco as “selective hepatic insulin resistance.” The practical result: hepatic glucose production continues at an elevated rate while triglyceride synthesis simultaneously accelerates. This explains the coexistence of elevated fasting glucose and hypertriglyceridemia characteristic of advancing insulin resistance. 5 / Solid

Endothelial function is a separate casualty. Insulin normally stimulates nitric oxide synthase activity in endothelial cells through the PI3K-Akt pathway, the same pathway that is blocked in insulin resistance. Impaired nitric oxide production reduces vasodilatory capacity, increases endothelial permeability to LDL particles, and promotes the expression of adhesion molecules that facilitate monocyte infiltration into the arterial wall. A 2021 meta-analysis in the European Heart Journal covering 14 studies and over 38,000 participants confirmed that flow-mediated dilation, the standard clinical measure of endothelial function, is inversely correlated with fasting insulin independent of other cardiovascular risk factors.

Cardiologist's Note

The lab value I want most in a new patient with borderline lipids is fasting insulin. I see it omitted from standard panels so routinely that I now include it on every initial workup I order. Here is why it matters in clinical practice.

A man in his late forties comes in for a preventive cardiology visit. His internist told him his cholesterol was “a little high” but otherwise fine. His fasting glucose is 96 mg/dL. His HbA1c is 5.6%. His LDL is 112 mg/dL. His blood pressure is 128/82 mmHg. By every conventional screening metric, he is borderline, not urgent. His fasting insulin comes back at 24 uIU/mL. His HOMA-IR is 5.7. His triglycerides are 204 mg/dL. His HDL is 36 mg/dL. His ApoB is 124 mg/dL. The LDL of 112 suggested moderate risk; the ApoB of 124 reflects a particle burden consistent with substantial risk. The fasting insulin is the thread that pulls the whole picture together.

What I look for in a new patient: waist circumference above 40 inches is my first clinical flag, because it is free and takes five seconds. If I see it, I know what the fasting insulin is likely to show, but I still order it because the number matters for the conversation. A patient who hears “your fasting insulin is 26, which means your pancreas is producing three times the normal insulin to keep your blood sugar normal” has a fundamentally different understanding of their situation than one who hears “your blood sugar is fine.” The first framing describes a process that is currently underway and will progress unless interrupted. The second framing describes a number, which carries no urgency.

The other marker I order routinely and rarely see on prior labs is ApoB. In patients with insulin resistance, there is a systematic mismatch between LDL and ApoB. The insulin resistance-driven VLDL overproduction increases the number of atherogenic particles while the particle composition shifts toward smaller, denser LDL. Standard LDL calculation underestimates particle number in exactly these patients. I have seen patients with LDL of 95 mg/dL and ApoB of 132 mg/dL. Treating to an LDL target in that patient means under-treating the actual risk. The Friedewald equation for LDL becomes progressively less accurate as triglycerides rise, precisely when it matters most to get the particle burden right.

The clinical pattern I find most common in men 45 to 60: fasting triglycerides between 160 and 240, HDL below 42, blood pressure creeping up from previously normal levels, waist circumference that has expanded 4 to 6 inches over the prior decade, and a fasting glucose that is normal. Every value is individually explainable. Together, they describe insulin resistance at a stage where intervention will have meaningful effect on long-term cardiovascular outcomes.

Sleep Deprivation as an Insulin Resistance Driver: The Overlooked Metabolic Input

The mechanisms described above, DAG/PKC-theta blocking IRS-1 signaling, visceral fat-driven portal free fatty acid delivery, and endothelial nitric oxide impairment, are driven primarily by nutritional and metabolic inputs. Sleep deprivation operates through partially distinct mechanisms to produce an overlapping clinical result, and the magnitude of the effect is underappreciated in standard metabolic management.

Spiegel and colleagues, publishing in The Lancet in 1999, restricted healthy young adults to four hours of sleep per night for six consecutive nights and measured glucose tolerance and insulin secretion with standardized testing. Six days of sleep restriction reduced glucose tolerance by approximately 40 percent and reduced insulin sensitivity by 30 percent. These are magnitudes comparable to early pharmacologically induced diabetes. The effect was rapidly reversible with sleep recovery, confirming that it was functional rather than structural.

The mechanisms are multiple. First, sleep deprivation activates the HPA axis, elevating cortisol during the second half of the night and carrying over into the following day. Cortisol promotes hepatic gluconeogenesis through activation of phosphoenolpyruvate carboxykinase and glucose-6-phosphatase, opposing insulin’s glucose-suppressive action specifically in the liver. Second, sleep deprivation alters appetite-regulating hormones: ghrelin rises while leptin falls, increasing caloric intake independent of energy expenditure changes. The resulting increase in substrate availability for hepatic lipogenesis adds further burden to the DAG/PKC mechanism described in the core mechanism section. Third, catecholamine release from sympathetic nervous system activation during fragmented sleep suppresses insulin secretion from pancreatic beta cells, reducing insulin supply at the same time peripheral resistance is rising.

The clinical implication is specific. A man addressing insulin resistance through dietary carbohydrate reduction, regular aerobic exercise, and visceral fat loss while sleeping five hours per night is managing three drivers of insulin resistance while actively maintaining a fourth. Fasting insulin will not fully normalize under those conditions because cortisol-mediated hepatic glucose production continues, appetite hormone dysregulation makes dietary adherence require more effort than it should, and insulin secretion is being intermittently suppressed. Sleep is not a lifestyle preference within the context of insulin resistance management. It is a metabolic variable, and treating it as optional degrades the clinical effectiveness of every other intervention in this article. 4 / Promising

What to Do This Week

Request fasting insulin alongside your next lipid panel. This requires a specific order from your physician; it is not included in a standard metabolic panel or lipid panel. Ask for fasting insulin and ApoB at the same visit. Collect the blood after at least 10 hours of fasting. A fasting insulin above 10 uIU/mL warrants attention; above 15 indicates significant resistance; above 25 indicates severe resistance with substantial cardiovascular implications.
Measure your waist circumference at the navel. Use a flexible tape measure, stand relaxed without pulling in your abdomen, and measure the circumference at the level of your navel. A measurement above 40 inches in men is the clinical threshold that correlates with visceral adiposity sufficient to drive insulin resistance. If you are above that number and your fasting triglycerides are above 150 mg/dL, you have the metabolic phenotype that insulin resistance produces, regardless of your fasting glucose.
Calculate your triglycerides-to-HDL ratio from your most recent lipid panel. Divide your fasting triglyceride value by your HDL value. A ratio above 3.0 in a non-diabetic adult correlates strongly with elevated ApoB particle burden and reflects insulin resistance-driven VLDL overproduction. A ratio above 5.0 reflects severe dyslipidemia warranting prompt evaluation. This calculation uses values you likely already have from prior standard labs.
Begin aerobic exercise at moderate intensity for 30 minutes, five days per week, within the next seven days. The mechanism is specific: aerobic exercise increases GLUT4 transporter expression in skeletal muscle, improving glucose uptake through a pathway that bypasses the blocked IRS-1 signal. A single session of moderate-intensity aerobic exercise, defined as 60 to 70% of maximum heart rate, improves insulin sensitivity for 24 to 48 hours in individuals with insulin resistance. Sustained training at this frequency produces lasting structural improvement in insulin signaling within 8 to 12 weeks. Walking briskly, cycling, swimming, and rowing all qualify. The effect is dose-dependent: more is better, and any start is better than none. 5 / Solid
Remove liquid caloric sources and reduce refined carbohydrate starting this week, not next month. Liquid calories, including juice, sweetened beverages, and alcohol, produce rapid hepatic glucose delivery that bypasses the intestinal regulatory mechanisms governing solid food absorption. Refined carbohydrates, including bread, white rice, breakfast cereals, and processed snacks, produce glycemic excursions that require elevated insulin responses and contribute to the chronic hyperinsulinemia that drives visceral fat accumulation. Reducing these two categories, before any other dietary change, reduces hepatic VLDL substrate and lowers the insulin demand on the pancreas. Fasting insulin begins to fall within two to four weeks of sustained dietary carbohydrate reduction in individuals with insulin resistance, as confirmed in controlled trials including the 2019 Virta Health study published in Frontiers in Endocrinology, which documented a mean fasting insulin reduction of 47% over 12 months in patients adhering to a low-carbohydrate dietary intervention.

Insulin resistance is not a condition that appears suddenly; it develops over years through the accumulation of visceral fat, physical deconditioning, and dietary patterns that keep insulin chronically elevated. The same gradual trajectory means that the reversal is also gradual, but measurable and confirmed in the clinical literature. Fasting insulin is the most specific early signal available, and the only reason most men with insulin resistance do not know they have it is that no one has yet ordered the test.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.

Start with the gap between how you appear and what your body is doing.

Take the Signal Check

Did this land?

The conversation

Join the men working through this in the open.